RLMD
Relmada Therapeutics Inc
3.60$
-1.6%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2012 | 2013 | 2014 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | +981.2% | +242.4% | +0.0% | +492.3% | +55.6% | -96.9% | -99.8% | +85,955.0% | -66.5% | -100.0% | – | – | – | |
| – | – | – | – | -59.7% | +51.5% | -41.6% | -26.5% | -99.5% | +752,427.1% | +94.9% | +9.1% | -0.9% | -31.1% | -50.4% | |
| – | – | – | -75.7% | -309.3% | – | – | +311.0% | -45.1% | +650.5% | +100.7% | -7.9% | – | – | – | |
| – | +633.4% | -54,360.0% | – | – | – | -114.8% | – | -100.0% | – | -172.5% | – | -70.9% | -151.4% | – | |
| – | – | +455.6% | +133.3% | +0.0% | +2,310.4% | -91.2% | -75.1% | -100.0% | – | – | -40.0% | +33.3% | -100.0% | – | |
| – | – | +596.9% | +86.0% | +0.0% | +2,310.4% | -91.2% | -75.1% | +547.0% | +42,871.5% | +57.1% | – | +155.7% | +2.2% | -193.4% | |
| – | – | +17,350.0% | +285.4% | – | – | – | – | +541.3% | – | – | – | – | – | – | |
| – | – | – | -160.9% | -10.2% | +3.8% | – | -104.4% | +29.3% | -70.1% | -100.0% | – | – | – | – | |
| – | +48.1% | +19,900.0% | +228.9% | +0.0% | -102.0% | +3.8% | – | -98.1% | +22,478.3% | +560.1% | -76.0% | -100.2% | -59.0% | – | |
| – | +6.8% | +27,498.2% | -276.8% | – | – | – | – | -98.7% | -484,307.0% | – | -193.1% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.